Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RICHI: Reduced-Intensity Conditioning for HLH and Immune Deficiencies
NCT01998633Phase 2Completed
- Sponsor
- Medical College of Wisconsin
- Start
- Dec 2013
- Primary completion
- Sep 2016
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of alemtuzumab in hemophagocytic lymphohistiocytosis (HLH), chronic active Epstein-Barr virus infection (CAEBV), chronic granulomatous disease (CGD), X-linked hyper IgM syndrome (X-HIGM), Immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX), sponsored by Medical College of Wisconsin. Started Dec 2013; status: completed.
02
Drugs
alemtuzumab
03
Conditions
hemophagocytic lymphohistiocytosis (HLH)chronic active Epstein-Barr virus infection (CAEBV)chronic granulomatous disease (CGD)X-linked hyper IgM syndrome (X-HIGM)Immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX)
Beyond the preview
Go deeper on NCT01998633.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01998633.